Next Generation Medicine
Personalized medical platform
BIOIMMUNATE TECHNOLOGIES Ltd. develops innovative personalized medical platform to treat autoimmune diseases. We create breakthrough precise medicine technology of blood filtration to autoimmune diseases based on removal of harm cells from the human body. BIOIMMUNATE current R&D is focused on multiple sclerosis (MS) patients
BIOIMMUNATE is focused on the quality of life of autoimmune disease patients. In particular, we will change the gold standard treatment approach to Multiple Sclerosis (MS) patients. BI’s ambitious goal of precision treatment will replace the MS pharmaceutical treatments that are accompanied by toxic side effects.
Improving the patient’s well-being is our mission and primary aim. Our goal is to treat MS patients 2-3 times a year, thereby enabling them to live healthy and balanced lives. Our innovative treatment paradigm is a revolutionary medical therapy.
Our management team, R&D team and Scientific Advisory Board include the highly experienced research, academic and business professionals required to build BIOIMMUNATE as a next generation immune therapeutics company that preserves a high quality of life for MS patients.
Replacing MS drugs with a non-pharmacological treatment
The Need
MS is an autoimmune disease that attacks myelinated axons in the central nervous system (CNS) to various degrees, causing significant physical disability. Current treatments are solely pharmacological; however, the existing medications are accompanied by severe adverse effects, do not stop disease progression, and increase the cost burden.
Our Mission
Developing and commercializing device-based solutions for autoimmune diseases, providing safer therapy without side effects and with superior cost-effectiveness. BI’s platform technology is initially focused on Multiple Sclerosis patients.
Combining real time data with targeted cell removing technology
Multiple Sclerosis
In the past 40 years, when a patient is diagnosed with an autoimmune disease, he is forced to a course of drug treatment that manages to reduce (at best) 30% of his auto-reactive cells, along with suppression of the entire immune system.
BIOIMMUNATE has developed an innovative method of removing only the auto-reactive cells from the bloodstream in a higher rate, without effecting the rest of the immune system.
Patients' Well-Being Instead of Toxic Side Effects
The Product
Brain damage in MS is caused by specific MS-related cells that migrate from the blood to the brain. BIOIMMUNATE has developed unique biological cell removal filter able to recognize, capture, and remove targeted cells from the blood before they reach the brain. BIOIMMUNATE’s technology will both stop the disease progression and prevent further damage to the brain; this ground-breaking technology will replace the drugs currently prescribed for MS treatment.
Stopping disease progression while maintaining Quality of Life.
Our Value Proposition
> Considerable improvement of patient life expectancy
and QoL.
> Safe procedure, no side effects are expected.
> Reduce healthcare & and reimbursement costs. Unmatched cost-effectiveness.
First in human trial - expected to initiate at 2022
Revolutionizing the Area of Medical Therapy
Regulatory Pathway
According to FDA’s formal designation the product is a combination product, assigned to the Center for Devices and Radiological Health (CDRH) as lead.
Experienced Research and Business Professionals
Go-To-Market
MS global multiple sclerosis drugs market was $25B in 2019 and is projected to reach $40B by 2027 (‘fortune business insights’)
KOLs
BIOIMMUNATE is backed by internationally renowned Key Opinion Leaders, who are members of the Company’s Scientific Advisory Board.